Myeloproliferative Neoplasms

Ruben A. Mesa, MD, discusses the approval of fedratinib in myelofibrosis and other JAK inhibitors in the treatment pipeline.

Aaron Gerds, MD, discusses the adverse event anemia in patients with myelofibrosis.

Neil Dunavin, MD, MS, discusses ongoing research on therapies for patients with myelofibrosis.

Ilaria Iacobucci, PhD, discusses integrated transcriptomic and genomic sequencing to identify prognostic constellations of driver mutations in AML and MDS.

Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses ongoing research with pacritinib in myelofibrosis.

Srikanth Nagalla, MD, discusses the utility of direct oral anticoagulants in patients with a myeloproliferative neoplasm–associated venous thromboembolism.

Neil Dunavin, MD, MS, discusses frontline treatment in myelofibrosis.

Neil Dunavin, MD, MS, highlights criteria to consider when approaching treatment selection for patients with myelofibrosis and discussed next steps for the field.

Jacqueline S. Garcia, MD, instructor in Medicine, Department of Medical Oncology, Harvard Medical School, and physician, Dana-Farber Cancer Institute, discusses research with the combination of navitoclax and ruxolitinib (Jakafi) in patients with myelofibrosis.

Ruben Mesa, MD, discusses theapproval of a second JAK inhibitor, fedratinib, to join ruxolitinib as a treatment option for patients with myelofibrosis.

Ruben A. Mesa, MD, director, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses the efficacy of fedratinib (Inrebic) in patients with myelofibrosis who have low platelet counts.

Raajit K. Rampal, MD, PhD, discusses unmet needs in the treatment of patients with myelofibrosis and polycythemia vera.

Treatment with luspatercept-aamt reduced the severity of anemia in patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts who require red blood cell transfusions.

Aaron Gerds, MD, discusses the future treatment of patients with myeloproliferative neoplasms through the use of JAK-STAT pathway.

Neil Dunavin, MD, MS, assistant professor of medicine, School of Medicine, University of California, San Francisco (UCSF), UCSF Helen Diller Family Comprehensive Cancer Center, discusses treatment considerations in myelofibrosis.

Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses treatment options in polycythemia vera.

CPI-0610 showed promising spleen volume responses and a meaningful reduction in total symptom score as monotherapy and in combination with ruxolitinib (Jakafi) for patients with refractory or intolerant advanced myelofibrosis.

Although several newer JAK inhibitors are being investigated, such as pacritinib, momelotinib, and the recently FDA-approved fedratinib, most combinations are being explored in combination with ruxolitinib.

Ruben Mesa, MD, discusses the JAKARTA and JAKARTA-2 studies and the implications their data have on the field of myelofibrosis.

Laura C. Michaelis, MD, discusses the integration of fedratinib into the treatment sequence of myelofibrosis.

James K. McCloskey II, MD, discussed current treatment options for patients with myelofibrosis as well as further options in development in clinical trials.

David S. Snyder, MD, associate chair, Department of Hematology and Hematopoietic Cell Transplantation, professor, Hematology and Hematopoietic Cell Transplantation, and hematologist/oncologist, City of Hope, discusses ongoing research dedicated to providing more curative options to patients with myelofibrosis.

The FDA has approved fedratinib (Inrebic) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis.

James M. Rossetti, DO, discusses strategies for symptom management, tools available for risk stratification, and updated data with some of the pivotal agents in myeloproliferative neoplasms.